Flying Lotus Unveils Three Previously Unheard Tracks, Two Featuring Thundercat

first_imgElectronic experimentalist Flying Lotus has just released three previously unheard tracks, which look to be products of his most recent original 2014 compilation You’re Dead!. He released a deluxe edition of the LP last year, and included 39 tracks of bonus cuts and instrumental outtakes. As if that wasn’t enough, we are now presented with three more tracks from the legendary studio session. Music really is the gift that keeps on giving.One of the new tracks, “TDC – Alt Experiment,” offers a fresh re-arrangement of the You’re Dead! track, “Turkey Dog Coma.” Additionally, LA-based producer shared two tracks with frequent collaborator and rising bass-god Thundercat, titled “Haleys Line//thundercat” and “NO Feeer Thunnderrrcatt2010.”Listen To Thundercat’s Funky New Untitled SongIn true FlyLo fashion, the three tracks came as complete surprises, with no lead-up or announcement whatsoever. Each recording, exponentially different from the rest, offers a deeper understanding of the artist and the particular brainwaves he chooses to share. Take a listen and fly away to the sweet combinations of these sounds:“NO Feeer Thunnderrrcatt2010”“Haleys Line//thundercat”“TDC – Alt Experiment”[H/T CoS]last_img read more

Gearing Up For Lettuce’s Rage Rocks With Amazing Footage From Last Year’s Show

first_imgIn just a few short weeks, premiere funk group Lettuce will return to one of most storied venues of all time, Red Rocks Amphitheatre, for a true musical celebration that could only be dubbed “Rage Rocks.” With The Wailers, Manic Focus, Pete Rock and Rahzel, the funk phenoms will let loose in Colorado on June 10th, and we couldn’t be more excited. Tickets are still available here.It seems like just yesterday that Lettuce joined forces with The Motet at Red Rocks for a glorious night of funk tunes. On June 6th 2015, Lettuce hit the stage, dropping funk bombs left and right on a thoroughly excited crowd. The band brought out tons of their classics, and even called on Nigel Hall to lend his vocals to their instrumental grooves. Check out our full review here.In celebration of the upcoming Red Rocks show, we wanted to throw it back with some footage from last year’s performance. Here are five choice cuts from Red Rocks 2015, sure to get you pumped up for Red Rocks 2016!By Any Shmeeans Necessary > Colorado Love > By Any Shmeeans NecessaryGet GreasyChiefPhyllisMakin’ My Way Back Home w/ Nigel HallAll videos were filmed by Jordan Inglee and mastered by Phil Salvaggio, for the purposes of Lettuce’s Live BitTorrent bundle. Lettuce’s Red Rocks throwdown, “Rage Rocks,” kicks off on June 10th, with support from The Wailers, Manic Focus, Pete Rock and Rahzel. Tickets are on sale now and can be found here!Check out last year’s setlist below.Setlist: Lettuce at Red Rocks Amphitheatre, Morrison, CO – 6/6/15Big Anthem, By Any Shmeeans Necessary > Colorado Love > By Any Shmeeans Necessary, Get Greasy, Chief, Phyllis, Breakout > Relax > Jesus Dre >  Trap > Madison Square, Squadlive > Lettsanity, Lett Zeppelin, Do It Like You Do > Makin’ My Way Back Homelast_img read more

A major test for dietary supplements

first_img We’re in the dark on dietary supplements. She’s working to change that. Related Harvard epidemiologist aims to sort fact from fiction on health claims in multibillion-dollar industry GAZETTE: And what about vitamin D?MANSON: There weren’t significant reductions in the primary endpoints of major cardiovascular events — combined heart attacks and stroke — or the total incidence of cancer. But we saw a signal for reduction in cancer death over time.The trial was 5.3 years, which is usually sufficient for CVD outcomes but is relatively short for cancer, due to its long latency period. It may take longer to see the effect on cancer incidence. Those cancers diagnosed in the early years of the trial were undoubtedly already present, subclinical, at the time the participants were enrolled. Previous studies suggest that vitamin D may work at later stages of cancer. What we saw, after accounting for latency period by excluding early follow-up, was a 25 percent reduction in cancer deaths.Laboratory and clinical studies suggest that vitamin D may affect tumor biology, making tumors less invasive, less aggressive, and less likely to metastasize. And if that’s the effect, once there’s already a tumor — diagnosed or not, clinically detected or not — you might see a reduction in cancer death over the course of a five-year trial.There were some findings by body mass index. If you were average weight or below, there did seem to be more of a benefit of the vitamin D on cancer incidence. If you have a higher body mass index, there may be a need for higher doses of vitamin D or maybe there’s a vitamin D resistance similar to insulin resistance. We really don’t know. But this warrants further study.I think these findings do need to be interpreted cautiously — they’re subgroup findings — but these are intriguing signals.GAZETTE: Is there a lesson here about the importance of considering different populations when you’re analyzing scientific research?MANSON: Although it’s biologically plausible that some groups will benefit more than others, the problem is that you always have to interpret subgroup analyses cautiously.With dietary supplements, it’s important to understand the nutrient status of the study participants and to see if those with lower dietary intake or lower nutrient status are more likely to benefit from the supplements. With omega-3s, of course you want to understand dietary intake, particularly fish consumption. The finding that those with lower fish consumption in VITAL were more likely to benefit from marine omega-3s adds to the biological plausibility.But here’s what’s really surprising. Previous randomized trials of omega-3 have rarely done diet assessments. And they’ve rarely looked at the modifying effect of fish consumption on the omega-3 benefit, in terms of who benefits and who doesn’t. So this is a strong advantage of the VITAL trial, that we had the diet assessment and we could stratify participants by diet and low-fish consumption.GAZETTE: Analysis of this data is continuing. Will you be looking at effects on other conditions?MANSON: Yes. We’re looking at many other health outcomes. We have 23 ancillary studies. We’re looking at diabetes, cognitive function, mood, depression, autoimmune disorders, lung diseases, infections, heart failure, and many other clinical conditions.GAZETTE: Any idea what the timing is on those?MANSON: We’re saying six to 12 months to have these ancillary studies published. And that will help to inform the benefit-risk profile of these supplements.Some people, if they’re not in a group that may particularly benefit — such as those with low fish consumption — they may want to stay tuned for the results of the ancillary studies, because these studies will help with their decision-making.GAZETTE: You mentioned follow-up studies as well.MANSON: We’re continuing to follow the study participants for at least two more years, and we’re going to apply for continued funding to follow for several more years after that. The cancer results in particular, due to the latency period, may take a while to become fully apparent.GAZETTE: What would be your recommendations to the public?MANSON: If you’re already taking these supplements, we don’t find clear reasons for stopping, but we caution against mega-dosing. The safety that we demonstrated for these doses — 2,000 IUs vitamin D, one gram a day of omega-3s — may not apply to much higher doses.And, if you fall into a group that appears to gain greater benefit, such as — with the omega-3s — those with low-fish consumption and African-Americans, you may want to talk to your health care provider about whether to take a supplement.But for most people, stay tuned, because we’re going to have results for ancillary studies — diabetes, cognition, depression, all these other outcomes.Also, it’s possible that over the next couple of years, medical and public health authorities will look at these findings and at the results of other randomized trials that have been done recently and see if clinical guidelines regarding these supplements should be updated.Interview was edited for clarity and length. Cocoa for pleasure — and health? Too sweet for our own goodcenter_img The VITAL study, supported by the National Institutes of Health and headed by JoAnn Manson, the Michael and Lee Bell Professor of Women’s Health at Harvard Medical School and a professor of epidemiology at the Harvard Chan School, sought to clear up confusion around two popular dietary supplements through an analysis whose design has long been considered the gold standard for clinical trials.Randomized and placebo-controlled, VITAL followed more than 25,000 people age 50 and older who took daily supplements containing vitamin D, omega-3 fatty acids, or placebo. The Gazette spoke with Manson about the results, which were published this month in The New England Journal of Medicine.Q&AJoAnn MansonGAZETTE: What gaps in knowledge was the study intended to fill?MANSON: It helped to fill several knowledge gaps. For omega-3 fatty acids, the previous randomized trials had largely been in high-risk populations with a history of cardiovascular disease (CVD) or with selected risk factors for CVD.VITAL is the first large-scale randomized trial of marine omega-3s in a general population at “usual risk” of CVD. It’s also one of the first randomized trials of these supplements in a racially and ethnically diverse study population. Assessing the role of these supplements in a general population free of cardiovascular disease and cancer at baseline fills an important gap in knowledge.There have been few large-scale randomized trials of moderate- to high-dose vitamin D in the prevention of cancer and CVD. Most of the vitamin D trials have been for bone health, preventing fractures. These tend to be smaller trials, and some of them have tested much lower doses, only 400 to 800 international units a day. We tested 2,000 IUs a day.GAZETTE: Why don’t we discuss omega-3 and vitamin D separately, since it seems there were several findings for each. Were the omega-3 findings clearer?MANSON: For the omega-3s, there were several findings pointing to a coronary benefit, though for the prespecified, primary endpoint of “major cardiovascular events” — heart disease plus stroke plus total CVD mortality — there was only a small, statistically nonsignificant 8 percent reduction. It’s likely that the lack of benefit for stroke diluted the results for the primary endpoint.But those who had low fish intake — fish is the primary source of marine omega-3s in the diet — had a statistically significant reduction in the primary endpoint, compared to placebo. The lower half of the distribution had a 19 percent reduction with treatment and, for heart attack alone, a 40 percent reduction.For the overall study population, we had several prespecified secondary endpoints, including looking at heart attack, stroke, and CVD mortality separately. We did see a 28 percent reduction in heart attack, but no significant reductions in stroke or CVD mortality. We also saw that African-Americans appeared to benefit the most in terms of heart attack reduction — a 77 percent reduction compared to the placebo group. Again, you have to interpret this cautiously. “Previous randomized trials of omega-3 have rarely done diet assessments. And they’ve rarely looked at the modifying effect of fish consumption on the omega-3 benefit.” Panel lauds new labeling guidelines, takes aim at added sugar and salt in food, as well as some supplements Massive study will try to determine benefits of much-loved, savory powder The Daily Gazette Sign up for daily emails to get the latest Harvard news.last_img read more

Professor appointed to White House council

first_imgThe Council of Economic Advisers (CEA) provides President Barack Obama with guidance on both foreign and domestic economic policy and helps inform White House policy decisions, and this year, the CEA includes a Notre Dame professor. Professor Abigail Wozniak, an associate professor of economics, began a one-year term as a senior economist at the CEA in July and said the position allows her to apply her academic interests and knowledge to tangible problems and solutions.“It’s a chance to answer questions that people need answered,” Wozniak said in a press release. “I’m looking forward to being able to use the training that I have in a way that helps the public interest.”Wozniak is not able to take press requests during her term for the CEA, but William Evans, chair of the economics department, said Wozniak has completed a broad range of research projects during her time at Notre Dame, with a specific focus on labor economics.In the past few years, Wozniak has taught courses on labor economics and the development of the American labor force. Dating back to 2005, when she began teaching at Notre Dame, Wozniak’s courses included “Principles of Microeconomics and Migration, Education and Assimilation: Three Forces that Built America.” She also teaches graduate-level economics classes.Evans said Wozniak’s position speaks to the high level of respect she commands as an economist.“I think the fact that she’s gotten a job with this sort of visibility indicates what the profession thinks of her,” he said. “There are a lot of really great economists who have had these staff positions at the same point in her career, so I think it’s a great opportunity for her. It’s indicative of what the profession thinks of her work, to have such a high-level and visible position.”Evans also said Wozniak’s position highlights the excellent work of the Notre Dame’s economics department, which he said is “relatively young,” growing from 11 faculty members when he arrived in 2007 to nearly 25 currently.“We want the profession at large to understand the good things that are going on here, and this is one way we get to publicize that,” he said.Kevin Rinz, a graduate economics student who also worked as a staff economist at the CEA from July 2013 until July 2014, said the work at the CEA differs vastly from an academic setting.“You spend a lot of time in meetings, on conference calls, writing memos, creating presentations, analyzing data and reading papers, but which of those things you do in a given day and the topics you cover vary substantially and are subject to change on very short notice,” he said. “The Council itself is composed of three people — the chairman and two members. The members help the chairman lead the organization. When CEA gets a request from another part of the White House or starts a new project of its own, one of the members usually works with the senior economists with relevant expertise to decide what direction CEA’s work will take. The senior economists and junior staff [including staff economists, research economists and research assistants] then carry out the analysis and report back to the member.”Rinz said the members then take requests to the chairman, who gives further direction until the project is complete. He also said CEA staff are free to pursue research topics that interest them and take them to the members and chairman.Evans said he hopes Wozniak’s experience at the CEA will help create a unique and innovative classroom experience when she returns in July 2015.“It would be nice to parlay this into some policy-based courses that students can benefit from,” he said. “But we’ll see, that’s going to be up to [Wozniak]. It’s a very different experience from teaching.”Rinz said working with the CEA can enhance academic research in a variety of  ways.“Since CEA’s focus is very broad and academics tend to focus on fairly narrow fields, you have to learn about a lot of topics in which you didn’t necessarily have pre-existing expertise when you work at CEA,” Rinz said. “This can help you discover new areas in which you would like to do research when you return to academia.“Also, perhaps more importantly for researchers interested in public policy, working at CEA shows you what issues policymakers consider important, how they think about them and what kind of evidence they find persuasive. This can be useful if you want policymakers to pay attention to your future research.”Tags: Council of Economic Advisers, economics, White Houselast_img read more

JCC Student Receives SUNY Chancellor’s Award

first_imgImage via Joana Leamon / Facebook.JAMESTOWN – A SUNY JCC student is among 213 students being honored with the State University of New York Chancellor’s Award of Student Excellence for academic achievement, leadership, and community service this year.Joana Leamon, of Silver Creek, graduated with an associate’s degree in communication from JCC in December. Leamon is also earning an associate’s degree in media arts and a certificate in multimedia production in May. She attained dean’s list status every semester and also completed JCC’s honors program.Leamon served as vice president of the JCC’s Alpha Kappa Beta Honor Society and as a peer mentor. She was named to the 2019 Phi Theta Kappa All-New York Academic Team and was a JCC Scholars Day 2019 winner.During her time at JCC, Leamon completed internships with JCC’s marketing department, Patterson Library’s Octagon Gallery in Westfield, and the Oliver Archives Center at Chautauqua Institution. She was a presenter during the “Five More Giants of Chautauqua” heritage lecture series in 2019. Leamon has volunteered at JCC’s Jamestown Campus and North County Center, JCC’s Weeks Gallery, and Christ Chapel Wesleyan Church.Leamon is transferring to Buffalo State College this fall to major in media production and plans to pursue a career in the media industry, focusing on documentary filmmaking or broadcasting.Although recipients are typically recognized in person in Albany, the ceremony was curtailed due to COVID-19 restrictions.The Chancellor’s Award for Student Excellence was created in 1997 to recognize students who have best demonstrated, and have been recognized for, the integration of academic excellence with accomplishments in the areas of leadership, athletics, community service, creative and performing arts, campus involvement, or career achievement.Each year, SUNY campus presidents establish a selection committee, which reviews the accomplishments of exemplary students. Nominees are forwarded to the Chancellor’s office for a second round of review. Finalists are recommended to the chancellor to become recipients of the award. Share:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to email this to a friend (Opens in new window)last_img read more

Nancy Opel & More Join Cast of Honeymoon in Vegas on Broadway

first_imgTony nominee Nancy Opel, David Josefsberg and Matthew Saldivar are heading to the Broadway strip. The three will join the previously announced Rob McClure, Brynn O’Malley and Tony Danza in the Broadway production of Honeymoon in Vegas. All six performers appeared in the world premiere of the musical at Papermill Playhouse last year. The show, which features a score by Tony winner Jason Robert Brown and a book by the 1992 film’s screenwriter Andrew Bergman, is set to begin performances on November 18 at Broadway’s Brooks Atkinson Theatre. Opening night is set for January 15, 2015. The production will feature set design by Anna Louizos, costumes by Brian C. Hemesath, lighting design by Howell Binkley, sound design by Scott Lehrer and Drew Levy and orchestrations by Don Sebesky with additional orchestrations by Larry Blank and Charlie Rosen. Additional casting will be announced at a later date.  Honeymoon in Vegas, directed by Gary Griffin, tells the story of Jack Singer (McClure), a commitment-phobe who finally proposes to his girlfriend Betsy (O’Malley). The couple heads to Vegas to get hitched, but when smooth-talking gambler Tommy Korman (Danza) falls head over heels for Betsy, he arranges for Jack to lose big in a poker game so he can claim the bride-to-be as his own girlfriend. Opel, who earned a Tony nod for her performance in Urinetown, is currently starring as Madame in Cinderella. Her additional stage credits include Memphis, The Toxic Avenger, Fiddler on the Roof, Sunday in the Park with George, Anything Goes, Triumph of Love and Evita. Josefsberg’s Broadway credits include The Wedding Singer, Grease and Les Miserables; off-Broadway, he was seen in Altar Boyz, Rated P for Parenthood and Slut. Saldivar most recently appeared on the Great White Way in Act One; he has also seen in Peter and the Starcatcher, The Wedding Singer, Grease and A Streetcar Named Desire. Related Showscenter_img View Comments Honeymoon in Vegas Show Closed This production ended its run on April 5, 2015last_img read more

This Week’s Picks! Rock Out with Hedwig’s Inch, Sing Shakespeare & More

first_img Rock Out with Hedwig’s Inch September 4 at the Mercury Lounge Take a three-hour nap, mainline caffeine, and be ready to party at midnight. After their regular gig as the latter half of Hedwig and the Angry Inch, the band Tits of Clay heads to the Mercury Lounge for a late night, straight-up rock show with special guests. Last time, it was Neil Patrick Harris and Lena Hall. If Andrew Rannells or John Cameron Mitchell want to stop by this time, we’re not complaining. Click for tickets! Enter the World of Normal September 2 at 54 Below You’ve seen Adam B. Shapiro in the The Normal Heart—now he’s spilling all the juicy details in person at New York theater hotspot 54 Below. His new solo show Nothing Normal, featuring special guest Danielle Ferland, is an “eclectic mix of songs and stories celebrating the hilarious and precarious sides of life” and anecdotes from the movie. Click for tickets! Hey, we know you’re sad that summer is officially over. But chin up, plucky theatergoers! There’s tons of cool stuff to make you forget the ice cream truck’s imminent demise. There’s Andrea Martin’s return to Pippin, a musical Shakespeare experience in Central Park, and bubbly Broadway star Annaleigh Ashford on your TV. It’s all part of this week’s picks! Get Chatty with Annaleigh Ashford September 1, check local listings Just because it’s the end of summer—noooo!—doesn’t mean you can’t end it on a high note. Tony nominee Annaleigh Ashford, now appearing in You Can’t Take It with You, stops by The Late Late Show with Craig Ferguson. We’re not sure what she’ll talk about: Her role on Masters of Sex, working with James Earl Jones, coal mining… So you’ll just have to have to watch! You can catch up on your sleep Tuesday. Catch Andrea Martin’s Return to Pippin Beginning September 2 at the Music Box Theatre Pippin has become a reunion-fest in recent months—not that we’re complaining. Look who’s come back! First, it was original Pippin star John Rubinstein. Then, Broadway vet Priscilla Lopez. Now it’s Andrea Martin, who won a Tony for originating Berthe in the acclaimed revival, returning to the hilarious role through September 21. Which former alumnus will return to the beloved musical next? Can we vote on that? Seriously. Click for tickets! Sing a Song of Shakespeare Beginning September 5 at the Delacorte Theater You know how a group of seemingly clashing elements can create something wonderful? Come watch The Odd Couple theory at work as Broadway stars (Lindsay Mendez, Christopher Fitzgerald), community members, and special guests (stars from Sesame Street and the New York Theatre Ballet) come together for Public Works’ musical adaptation of Shakespeare’s The Winter’s Tale. Good news: It’s free. Bad news: It only runs through September 7. So geteth goingeth. Click for tickets! View Commentslast_img read more

Orange Cane Blotch

first_imgUniversity of Georgia researchers have found a treatment that kills up to 70 percent of a disease that attacks blackberry plants. “Plants can decline because of the algae, and other organisms can come in and kill the cane,” said UGA plant pathologist Phil Brannen. “That seems to be the biggest issue.”Jeremy Taylor, UGA Extension coordinator in Lanier and Clinch counties, has seen orange cane blotch wipe out several feet of a blackberry row, sometimes a whole row. Five Georgia blackberry growers with orange cane blotch problems have reported economic losses to Taylor. Since discovering ProPhyt as an effective fungicide last year, orange cane blotch has been reduced by 60 to 70 percent throughout the Southeast, Brannen said. According to the UGA’s 2013 Farm Gate Value Report, Lanier County produced $3.6 million in blackberries, making it the top producer in the state. Clinch County was in the top five producers in the state with $1.2 million. Georgia produced more than $10.8 million in blackberries. “We know that the disease causes a loss of berries,” Taylor said. “Some Florida growers have been completely put out of business by the disease.” Orange cane blotch is an algal disease that produces orange, yellow or sometimes green spots on blackberry plant canes. After the disease dies, the cane dries out and cracks, allowing infection by other diseases, such as cane blight. “Extension agents are integral in helping to solve these kinds of issues,” Brannen said. “They have helped with the trials, applied the material and worked with growers to get good research. We’re all working together to solve the problem, and that’s what we need.” Wet and humid conditions in 2013 were favorable for the disease. Last year, though, was much drier and the disease occurred two months later than it did in 2013. Brannen thinks the disease arrives in early spring when it’s wet, but infections can continue throughout the year. “It is absolutely critical for growers to be able to control this disease,” Taylor said. “It’s a big problem and one of the more difficult diseases that blackberry growers have to manage.”A team of UGA Extension agents plans to continue the research this growing season. Taylor, along with UGA Extension agents Eddie Beasley, in Berrien County, and Justin Shealy, in Echols County, want to better understand the pathogen and discover additional fungicide options should the disease become resistant to ProPhyt. The agents will also look for other chemicals to apply with ProPhyt. During the fungicide trials that led to the discovery of the efficacy of ProPhyt, UGA researchers sprayed 13 fungicides on a commercial blackberry farm in Lanier County. The results, showing ProPhyt as the most effective, were distributed to local producers. Growers throughout the Southeast now use the fungicide. UGA College of Agricultural and Environmental Sciences research trials found ProPhyt, a phosphonate fungicide, is an effective management tool for orange cane blotch disease in blackberries. As of 2015, ProPhyt is only labeled for two applications per year. Taylor said growers need to spray every two to three weeks. (Jordan Hill is an intern with the College of Agricultural and Environmental Sciences.)last_img read more

Vermont Ag agency institutes new ‘Farm First’ dairy program

first_imgThe Vermont Agency of Agriculture is very pleased to announce the beginning of a new benefit for Dairy Producers and their Families: FARM FIRST (FFP). The FARM FIRST Program was developed and is operated by the Invest Employee Assistance Program (EAP) in collaboration with the Vermont Agency of Agriculture, the University of Vermont Extension, and the VT Farm Health Task Force. FARM FIRST now partners with dairy producers to provide information and counseling services that are tailored to their unique and changing needs.FARM FIRST is intended to improve mental health and productivity among farmers and family members on Vermont’s dairy farms. The first of its kind in the country, FARM FIRST takes the valuable Midwest farmer hotline model to a new level with the addition of statewide licensed clinical staff prepared to confidentially assist with any concern. Farmers’ concerns currently being addressed include:FinancialLegalFarm transfer or retirementHealth care services – personal stress, depression, anxiety, sleep deprivation, etc.IsolationRelationship conflictBusiness challengesPersonnel management quandaries. In addition to providing confidential consultation and counseling, FFP staff researches needs and provides current information and pertinent referrals to farmers who work day and night to keep their farms running. Agricultural experts in both the public and private sectors are consulted by FFP staff to provide links and valid information for Vermont dairy farmers.FARM FIRST’s membership card was sent to each Vermont dairy farm in February 2010. To reach a counselor, farmers call a dedicated toll-free counseling line, talk with a counselor about the issue at hand and are offered in-person counseling appointments and concrete help with resources. The FFP website, investeap.org/AgHome.htm provides abundant information on a wide range of topics as well as access to the FFP via e-mail.Dairy farmers say that they tend to business concerns before just about anything else, and they are reluctant to leave the farm except in a dire emergency. Through a phone call or e-mail to the FFP, farmers immediately receive personalized assistance. This assistance allows them to run their businesses with greater focus which in turn reduces the likelihood of accidents. Outreach is ongoing to keep FFP accessible to Vermont’s agricultural community.Seventeen individuals received assistance from FARM FIRST during its first two months. Word is spreading that Vermont dairy producers now have a confidential place to call with questions, worries and crises.Vermont’s Secretary of Agriculture, Roger Albee:“We need to find creative ways to support our dairy farm families as they continue to face serious challenges. The FARM FIRST program is an invaluable resource to assist with many difficult situations. We are extremely appreciative of all the groups who have come together to sponsor the program and who recognize the contributions dairy farmers offer to our economy and communities.”Source: Vermont Agency of Agriculture. 5.13.2010. For more information about FARM FIRST, please call the FFP administrative line at 1-888-392-0050.last_img read more

Miller Developments disposals give 3% uplift

first_imgTo access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletterslast_img